

## Letters

- Limiting production of crystal meth
- A question of ethics

## Limiting production of crystal meth

I read with interest the recent Public Health piece on methamphetamine hydrochloride (crystal meth).<sup>1</sup> Two subsequent articles on the same topic provided more details, but there were no comments on prevention programs or on limiting production of this drug.<sup>2,3</sup>

I had a distinct sense of déjà vu. Forty-five years ago, I reported in *CMAJ* the first North American case of addiction to diethylpropion.<sup>4</sup> This drug is chemically distinct from amphetamines, but the symptoms resulting from abuse are identical to those described by Buxton and Dove.<sup>1</sup> The only difference is one of degree.

My hospital colleagues and I believed that limiting availability was the best way to deal with the abuse problem. We persuaded the manufacturer to have the product made available by prescription, not on demand. This reduced the problem significantly.

I would suggest the same approach be used to address the illegal manufacture of crystal meth. It is clear that the manufacturing process is widely known. Is there any chemical used in the production of crystal meth that could be made subject to licensing if it were purchased in large quantities?

### Joseph Caplan

Honourary Consultant Psychiatrist, North York General Hospital, Toronto, Ont.

**Competing interests:** None declared.

### REFERENCES

1. Buxton JA, Dove NA. The burden and management of crystal meth use. *CMAJ* 2008;178:1537-40.

2. Cronkwright Kirkos W, Carrique T, Griffen K, et al. The York Region Methamphetamine Strategy. *CMAJ* 2008;178:1655-6.
3. Kish SJ. Pharmacologic mechanisms of crystal meth. *CMAJ* 2008;178:1679-82.
4. Caplan J. Habituation to diethylpropion (Tenuate). *CMAJ* 1963;88:943-4.

DOI:10.1503/cmaj.1080091

### [One of the authors responds:]

Joseph Caplan's suggestion that the chemicals involved in the synthesis of methamphetamine hydrochloride be regulated is highly relevant to the prevention of crystal meth use, but this issue was outside the scope of my review article.<sup>1</sup> Canada's Precursor Control Regulations include requirements, as Caplan recommends, to control precursors and other substances used in the production of methamphetamine, including ephedrine, pseudoephedrine and red phosphorus.<sup>2</sup> Before 2003 these regulations did not exist and there was much concern, especially in the United States, about the export of precursors from Canada for illicit methamphetamine production.<sup>3</sup> It can be argued that the Canadian legislation should be strengthened by requiring more frequent reporting by the chemical industry of the sale of precursors, by requiring licensing of end-users and by other approaches such as requiring that anhydrous ammonia (a nitrogen fertilizer used in methamphetamine synthesis) be stored in government-approved containers.<sup>4</sup>

There is also the controversial (at least in Ontario) question whether cold medications containing pseudoephedrine should be sold only in pharmacies (i.e., not in corner grocery stores) and only behind the counter so that the extent of use can be better monitored. Because of a severe problem with methamphetamine abuse, Oklahoma has required that such cold medications be sold only behind pharmacy counters in this state. Curious about the availability of pseudoephedrine in Canada, I contacted a Canadian Internet pharmacy and visited a major Canadian drugstore: the Internet pharmacy would sell customers only 60 tablets of a medication containing pseudoephedrine whereas in the drugstore the quantity

that customers could purchase was limited only by the availability of the drug.

It is obvious that methamphetamine precursors used for legitimate purposes must be tightly controlled. However, it now appears that precursors smuggled from outside of the country are often used to manufacture methamphetamine in Canada.<sup>5</sup> Drug prevention using precursor control thus remains a challenge.

### Stephen Kish PhD

Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ont.

**Competing interests:** None declared.

### REFERENCES

1. Kish SJ. Pharmacologic mechanisms of crystal meth. *CMAJ* 2008;178:1679-82.
2. Office of Controlled Substances. Regulatory requirements under the Controlled Drugs and Substances Act (CDSA): precursor control regulations (PCR) international. Ottawa: Health Canada; 2007. Available: [www.hc-sc.gc.ca/dhp-mps/substancontrol/chem-chim/international-eng.php](http://www.hc-sc.gc.ca/dhp-mps/substancontrol/chem-chim/international-eng.php) (accessed 2008 Aug 7).
3. Office of the Press Secretary. US releases annual narcotics certification report [press release]. Washington: The White House; 2003 Jan 31. Available: [www.usis.it/file2003\\_01/alia/a3013106.htm](http://www.usis.it/file2003_01/alia/a3013106.htm) (accessed 2008 Aug 7).
4. Government of Manitoba. Safeguard your supply of anhydrous ammonia. Winnipeg: Government of Manitoba; 2008. Available: [www.gov.mb.ca/agriculture/news/crystalmeth\\_en.pdf](http://www.gov.mb.ca/agriculture/news/crystalmeth_en.pdf) (accessed 2008 Aug 7).
5. National Drug Intelligence Center. National drug threat assessment 2008: methamphetamine. Johnston (PA): The Center; 2007. Available: [www.justice.gov/ndic/pubs25/25921/meth.htm](http://www.justice.gov/ndic/pubs25/25921/meth.htm) (accessed 2008 Aug 7).

DOI:10.1503/cmaj.1080092

## A question of ethics

In his review of the pharmacologic mechanisms of methamphetamine hydrochloride (crystal meth),<sup>1</sup> Stephen Kish made no mention of the fact that the so-called research in one of the articles he cited<sup>2</sup> was conducted at a military hospital in a military dictatorship. Kish also failed to mention that the article contained no indication of ethics approval. The neurosurgical intervention described in this study was performed first on rats and then on people who apparently gave their consent freely.

I believe that members of the medical community should not refer to such

articles, except to condemn the wanton disregard for research ethics and human rights. We are, first and foremost, physicians caring for patients, not social architects or subcontractors for repressive regimes.

**Mark Dubé MD**

Sudbury, Ont.

**Competing interests:** None declared.

**REFERENCES**

1. Kish SJ. Pharmacologic mechanisms of crystal meth. *CMAJ* 2008;178:1679–82.
2. Gao G, Wang X, He S, et al. Clinical study for alleviating opiate drug psychological dependence by a method of ablating the nucleus accumbens with stereotactic surgery. *Stereotact Funct Neurosurg* 2003;81:96–104.

DOI:10.1503/cmaj.1080085

**[The author responds:]**

The investigation about which Mark Dubé raises concerns involved treatment for patients addicted to opiate drugs in which a surgical lesion was made in a brain region (nucleus accumbens) considered to influence addiction to abused drugs.<sup>1</sup> The study reported partial success of the procedure.

Dubé feels that the study should not have been cited because the investiga-

tion was conducted in China and at a military-affiliated hospital (Tangdu Hospital) and, therefore, there would be ethical problems concerning lack of consent. As a point of clarification, my understanding from my Chinese colleagues is that it is likely that most patients at Tangdu Hospital in China are from the public.

I chose to cite the article in my review<sup>2</sup> because the article stated explicitly that patients underwent surgery “of their own free will”<sup>1</sup> and because I do not feel that the fact that a human study is conducted in China is sufficient grounds to dismiss the findings. I recognize that there will be those who feel that such consent cannot be freely given in China. I note that the same group described their consent process in more detail in a subsequent article: “All patients gave written informed consent according to the Declaration of Helsinki, and the study was approved by the local ethics committee.”<sup>3</sup>

The data from the study that I cited in my review were presented at the 2003 meeting of the American Society for Stereotactic and Functional Neurosurgery and published as a full article in the society’s journal as part of the conference proceedings.<sup>2</sup> The Tangdu Hos-

pital group’s other study discussed above was published in the same journal.<sup>3</sup> I mention this only parenthetically; I do not mean to imply that only human studies published in Western journals should be considered for citation.

In my review, I expressed my opinion that the findings from the article in question are preliminary. I did not cite the article as providing a potential strategy for treatment of drug addiction but only as providing limited evidence suggesting possible involvement of one brain region in drug addiction.

**Stephen Kish PhD**

Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ont.

**Competing interests:** None declared.

**REFERENCES**

1. Gao G, Wang X, He S, et al. Clinical study for alleviating opiate drug psychological dependence by a method of ablating the nucleus accumbens with stereotactic surgery. *Stereotact Funct Neurosurg* 2003;81:96–104.
2. Kish SJ. Pharmacologic mechanisms of crystal meth. *CMAJ* 2008;178:1679–82.
3. Guo H, Gao G, Wang X, et al. Effects of bilateral deep brain stimulation of the subthalamic nucleus on olfactory function in Parkinson’s disease patients. *Stereotact Funct Neurosurg* 2008;86:237–44.

DOI:10.1503/cmaj.1080086